Stocks Health care PROF
NASDAQ · Health careProfound Medical Corp. (PROF)
Profound Medical Corp. brought in $23.6M of revenue over the twelve months to September 30, 2026, up 65.3% from a year earlier. It posted a net loss of $32.5M. In fiscal 2025 capital spending exceeded operating cash flow by $38.4M. At September 30, 2026 it held $33.3M in cash against $4.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Profound Medical Corp.
- Net worth
- Profound Medical Corp. has a market value (market cap) of $280.6M at the latest share price, and shareholders' equity of $42.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $16.1M (+50.7% year on year), with a net loss of $42.6M. Over the 12 months to September 30, 2026: revenue $23.6M, net loss $32.5M.
- Cash flow
- In fiscal 2025 operations used $38.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Profound Medical Corp.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Profound Medical Corp. does
Profound Medical Corp. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker PROF.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $16.1M | -$42.6M | $1.41 | -$38.4M |
| 2024 | $10.7M | -$27.8M | $1.12 | n/a |
| 2023 | $7.2M | -$28.3M | $1.34 | n/a |
| 2022 | $6.7M | -$28.7M | $1.38 | n/a |
| 2021 | $6.9M | -$30.7M | $1.50 | -$22.4M |
| 2020 | $7.3M | -$21.6M | $1.25 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PROF ranks in Health care
Latest SEC filings
What Profound Medical Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 86% to $9.8M versus the same quarter last year; diluted EPS -$0.21 versus -$0.26.
- November 5, 2026
- November 3, 2026
- October 22, 2026
- October 14, 2026
- October 9, 2026
- October 7, 2026Quarterly results8-KProfound Medical reported preliminary third quarter 2026 revenue of $9.8 million to $10.0 million, representing strong year-over-year and sequential growth.
- September 4, 2026
- September 3, 2026
Insider trades
What the people running Profound Medical Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns PROF
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Neil Gagnon13G, passive with 2 related filers | 11.2% | January 23, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 56 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| FIL Ltd | 2,370,000 | +30,000 |
| Gagnon Securities LLC | 1,960,074 | +15,750 |
| Royce & Associates LP | 1,199,564 | +83,216 |
| Timelo Investment Management Inc. | 1,114,967 | 0 |
| Gagnon Advisors, LLC | 962,186 | 0 |
| First Eagle Investment Management, LLC | 880,414 | +557,707 |
| Rosalind Advisors, Inc. | 828,118 | 0 |
| Z3 Capital Partners, LLC | 820,941 | +2,950 |
| Letko, Brosseau & Associates Inc | 935,725 | -17,450 |
| MMCAP International Inc. SPC | 671,356 | -73,796 |
| Ardsley Advisory Partners LP | 575,000 | 0 |
| Ring Mountain Capital, LLC | 511,917 | +812 |
| Lagoda Investment Management, L.P. | 501,325 | +60,310 |
| Royal Bank of Canada | 491,495 | -1,565 |
| DAFNA Capital Management LLC | 260,360 | -2,645 |
| Bleichroeder LP | 254,753 | 0 |
| Formula Growth Ltd | 240,088 | -1,050 |
| Thompson Davis & CO., Inc. | 216,535 | +750 |
| Dauntless Investment Group, LLC | 208,369 | -32,370 |
| Raymond James Financial Inc | 189,116 | +38,959 |
Insiders
Questions about PROF
What does Profound Medical Corp. do?
Profound Medical Corp. is a company in the Health care sector, listed on NASDAQ as PROF. Its shares trade on NASDAQ under the ticker PROF.
What is Profound Medical Corp.'s net worth?
Profound Medical Corp. has a market value (market cap) of $280.6M at the latest share price, and shareholders' equity of $42.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Profound Medical Corp. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $32.5M on revenue of $23.6M.
How much revenue does Profound Medical Corp. make?
Over the twelve months to September 30, 2026 Profound Medical Corp. reported revenue of $23.6M. That is 65.3% more than a year earlier.
When did Profound Medical Corp. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the investor disclosure from November 9, 2026.
When is Profound Medical Corp.'s next earnings report?
Profound Medical Corp.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PROF with
Follow PROF
Get an email when Profound Medical Corp. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Profound Medical Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.